• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Avantor® Reports Second Quarter 2024 Results

    7/26/24 6:05:00 AM ET
    $AVTR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $AVTR alert in real time by email
    • Net sales of $1.70 billion, decrease of 2.4%; organic decline of 2.0%
    • Net income of $93 million; Adjusted EBITDA of $306 million
    • Diluted GAAP EPS of $0.14; adjusted EPS of $0.25
    • Operating cash flow of $281 million; free cash flow of $235 million

    RADNOR, Pa., July 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its second fiscal quarter ended June 30, 2024.



    "Our teams delivered another solid quarter with sequential improvements to all key financial metrics. Improved mix from increased bioprocessing revenue together with the accelerated impact of our cost transformation initiative drove more than 100 basis points of sequential Adjusted EBITDA margin expansion, while disciplined working capital management led to free cash flow conversion above 100%," said Michael Stubblefield, President and Chief Executive Officer.

    Avantor. Setting science in motion to create a better world. (PRNewsfoto/Avantor)

    "We are reaffirming our fiscal year 2024 guidance and remain focused on executing our long-term growth strategy and delivering value to our customers and shareholders," Stubblefield concluded.

    Second Quarter 2024

    For the three months ended June 30, 2024, net sales were $1,702.8 million, a decrease of 2.4% compared to the second quarter of 2023. Foreign currency translation had a negative impact of 0.4%, resulting in a sales decline of 2.0% on an organic basis.

    Net income increased to $92.9 million from ($7.3) million in the second quarter of 2023, and adjusted net income was $168.0 million as compared to $186.4 million in the comparable prior period. Net Income margin was 5.5%. Adjusted EBITDA was $305.6 million and Adjusted EBITDA margin was 17.9%. Adjusted Operating Income was $277.2 million and Adjusted Operating Income margin was 16.3%.

    Diluted earnings per share on a GAAP basis was $0.14, while adjusted EPS was $0.25.

    Operating cash flow was $281.1 million, while free cash flow was $235.3 million. Adjusted net leverage was 3.9x as of June 30, 2024.

    Second Quarter 2024 – Segment Results

    Laboratory Solutions

    • Net sales were $1,155.7 million, a reported decrease of 3.2%, as compared to $1,193.8 million in the second quarter of 2023. Sales declined 2.7% on an organic basis.
    • Adjusted Operating Income was $150.9 million as compared to $179.7 million in the comparable prior period. Adjusted Operating Income margin was 13.1%.

    Bioscience Production

    • Net sales were $547.1 million, a reported decrease of 0.5%, as compared to $550.1 million in the second quarter of 2023. Sales declined 0.3% on an organic basis.
    • Adjusted Operating Income was $144.0 million, as compared to $154.2 million in the comparable prior period. Adjusted Operating Income margin was 26.3%.

    Adjusted Operating Income is Avantor's segment reporting profitability measure under generally accepted accounting principles and is used by management to measure and evaluate the performance of our Company's business segments.

    Conference Call

    We will host a conference call to discuss our results today, July 26, 2024, at 8:00 a.m. Eastern Time. The live webcast and presentation, as well as a replay, will be available on the investor section of Avantor's website.  

    About Avantor

    Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

    Use of Non-GAAP Financial Measures

    To evaluate our performance, we monitor a number of key indicators. As appropriate, we supplement our results of operations determined in accordance with U.S. generally accepted accounting principles ("GAAP") with certain non-GAAP financial measures that we believe are useful to investors, creditors and others in assessing our performance. These measures should not be considered in isolation or as a substitute for reported GAAP results because they may include or exclude certain items as compared to similar GAAP-based measures, and such measures may not be comparable to similarly titled measures reported by other companies. Rather, these measures should be considered as an additional way of viewing aspects of our operations that provide a more complete understanding of our business. We strongly encourage investors to review our consolidated financial statements included in reports filed with the SEC in their entirety and not rely solely on any one single financial measure or communication.

    The non-GAAP financial measures used in this press release are sales growth (decline) on an organic basis, Adjusted Operating Income, Adjusted Operating Income margin, Adjusted EBITDA, Adjusted EBITDA margin, adjusted net income, adjusted EPS, adjusted net leverage, free cash flow, and free cash flow conversion.

    • Sales growth (decline) on an organic basis eliminates from our reported net sales growth (decline) the impacts of revenues from any acquired businesses that have been owned for less than one year and changes in foreign currency exchange rates. We believe that this measure is useful to investors as a way to measure and evaluate our underlying commercial operating performance consistently across our segments and the periods presented. This measure is used by our management for the same reason.
    • Adjusted Operating Income is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) losses on extinguishment of debt, (v) charges associated with the impairment of certain assets, (vi) and certain other adjustments. Adjusted Operating Income margin is Adjusted Operating Income divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason. Additionally, Adjusted Operating Income is our segment reporting profitability measure under GAAP.
    • Adjusted EBITDA is our net income or loss adjusted for the following items: (i) interest expense, (ii) income tax expense, (iii) amortization of acquired intangible assets, (iv) depreciation expense, (v) losses on extinguishment of debt, (vi) charges associated with the impairment of certain assets, (vii) and certain other adjustments. Adjusted EBITDA margin is Adjusted EBITDA divided by net sales as determined under GAAP. We believe that these measures are useful to investors as ways to analyze the underlying trends in our business consistently across the periods presented. These measures are used by our management for the same reason.
    • Adjusted net income is our net income or loss first adjusted for the following items: (i) amortization of acquired intangible assets, (ii) losses on extinguishment of debt, (iii) charges associated with the impairment of certain assets, (iv) and certain other adjustments. From this amount, we then add or subtract an assumed incremental income tax impact on the above-noted pre-tax adjustments, using estimated tax rates, to arrive at Adjusted Net Income. We believe that this measure is useful to investors as a way to analyze the business consistently across the periods presented. This measure is used by our management for the same reason.
    • Adjusted EPS is our adjusted net income divided by our diluted GAAP weighted average share count adjusted for anti-dilutive instruments. We believe that this measure is useful to investors as an additional way to analyze the underlying trends in our business consistently across the periods presented. This measure is used by our management for the same reason.
    • Adjusted net leverage is equal to our gross debt, reduced by our cash and cash equivalents, divided by our trailing 12-month Adjusted EBITDA (excluding stock-based compensation expense and including the expected run-rate effect of cost synergies and the incremental results of completed acquisitions as if those acquisitions had occurred on the first day of the trailing 12-month period). We believe that this measure is useful to investors as a way to evaluate and measure the Company's capital allocation strategies and the underlying trends in the business. This measure is used by our management for the same reason.
    • Free cash flow is equal to our cash flow from operating activities, plus acquisition-related costs paid in the period, less capital expenditures. Free cash flow conversion is free cash flow divided by adjusted net income. We believe that these measures are useful to investors as they provide a view on the Company's ability to generate cash for use in financing or investment activities. These measures are used by our management for the same reason.

    Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the tables accompanying this release.

    Forward-Looking and Cautionary Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this press release are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, including our cost transformation initiative, objectives, future performance and business. These statements may be preceded by, followed by or include the words "aim," "anticipate," "assumption," "believe," "continue," "estimate," "expect," "forecast," "goal," "guidance," "intend," "likely," "long-term," "near-term," "objective," "opportunity," "outlook," "plan," "potential," "project," "projection," "prospects," "seek," "target," "trend," "can," "could," "may," "should," "would," "will," the negatives thereof and other words and terms of similar meaning.

    Forward-looking statements are inherently subject to risks, uncertainties and assumptions; they are not guarantees of performance. You should not place undue reliance on these statements. We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. Factors that could contribute to these risks, uncertainties and assumptions include, but are not limited to, the factors described in "Risk Factors" in our most recent Annual Report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as such risk factors may be updated from time to time in our periodic filings with the SEC.

    All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. In addition, all forward-looking statements speak only as of the date of this press release. We undertake no obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise other than as required under the federal securities laws.

    Investor Relations Contact

    Christina Jones

    Vice President, Investor Relations

    Avantor

    +1 805-617-5297

    [email protected]

    Media Contact

    Emily Collins

    Vice President, External Communications

    Avantor

    +1 332-239-3910

    [email protected]

     

    Avantor, Inc. and subsidiaries 

    Unaudited condensed consolidated statements of operations 



    (in millions, except per share data)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2024



    2023



    2024



    2023

    Net sales

    $   1,702.8



    $   1,743.9



    $   3,382.6



    $   3,524.2

    Cost of sales

    1,121.3



    1,153.9



    2,230.6



    2,309.4

    Gross profit

    581.5



    590.0



    1,152.0



    1,214.8

    Selling, general and administrative expenses

    405.7



    357.5



    829.9



    751.1

    Impairment charges

    —



    160.8



    —



    160.8

    Operating income

    175.8



    71.7



    322.1



    302.9

    Interest expense, net

    (60.9)



    (73.4)



    (125.2)



    (147.1)

    Loss on extinguishment of debt

    (1.9)



    (1.6)



    (4.4)



    (3.9)

    Other income, net

    1.6



    2.0



    2.7



    2.6

    Income (loss) before income taxes

    114.6



    (1.3)



    195.2



    154.5

    Income tax expense

    (21.7)



    (6.0)



    (41.9)



    (40.3)

    Net income (loss)

    $       92.9



    $        (7.3)



    153.3



    114.2

















    Earnings (Loss) per share:















    Basic

    $       0.14



    $      (0.01)



    $       0.23



    $       0.17

    Diluted

    $       0.14



    $      (0.01)



    $       0.22



    $       0.17

    Weighted average shares outstanding:















    Basic

    679.4



    675.3



    678.7



    675.0

    Diluted

    682.6



    675.3



    681.9



    677.9

     

    Avantor, Inc. and subsidiaries 

    Unaudited condensed consolidated balance sheets 



    (in millions)

    June 30, 2024



    December 31, 2023

    Assets







    Current assets:







    Cash and cash equivalents

    $                272.6



    $                262.9

    Accounts receivable, net

    1,129.0



    1,150.2

    Inventory

    795.6



    828.1

    Other current assets

    132.0



    143.7

    Total current assets

    2,329.2



    2,384.9

    Property, plant and equipment, net

    753.8



    737.5

    Other intangible assets, net

    3,582.8



    3,775.3

    Goodwill, net

    5,659.6



    5,716.7

    Other assets

    368.1



    358.3

    Total assets

    $            12,693.5



    $            12,972.7

    Liabilities and stockholders' equity







    Current liabilities:







    Current portion of debt

    $                258.4



    $                259.9

    Accounts payable

    657.4



    625.9

    Employee-related liabilities

    146.1



    133.1

    Accrued interest

    49.9



    50.2

    Other current liabilities

    352.8



    411.2

    Total current liabilities

    1,464.6



    1,480.3

    Debt, net of current portion

    4,856.6



    5,276.7

    Deferred income tax liabilities

    575.4



    612.8

    Other liabilities

    361.9



    350.3

    Total liabilities

    7,258.5



    7,720.1

    Stockholders' equity:







    Common stock including paid-in capital

    3,897.5



    3,830.1

    Accumulated earnings

    1,644.8



    1,491.5

    Accumulated other comprehensive loss

    (107.3)



    (69.0)

    Total stockholders' equity

    5,435.0



    5,252.6

    Total liabilities and stockholders' equity

    $            12,693.5



    $            12,972.7

     

    Avantor, Inc. and subsidiaries 

    Unaudited condensed consolidated statements of cash flows 



    (in millions)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2024



    2023



    2024



    2023

    Cash flows from operating activities:















    Net income (loss)

    $      92.9



    $      (7.3)



    $    153.3



    $    114.2

    Reconciling adjustments:















    Depreciation and amortization

    102.6



    102.6



    202.2



    203.7

    Impairment charges

    —



    160.8



    —



    160.8

    Stock-based compensation expense

    11.1



    9.2



    23.8



    21.9

    Provision for accounts receivable and inventory

    15.5



    30.6



    39.5



    43.1

    Deferred income tax benefit

    (34.8)



    (38.3)



    (52.7)



    (64.7)

    Amortization of deferred financing costs

    2.8



    3.3



    5.8



    6.7

    Loss on extinguishment of debt

    1.9



    1.6



    4.4



    3.9

    Foreign currency remeasurement (gain) loss

    (2.2)



    (1.9)



    3.1



    (0.1)

    Changes in assets and liabilities:















    Accounts receivable

    (2.7)



    60.1



    —



    7.9

    Inventory

    (3.2)



    (8.8)



    (14.2)



    (1.7)

    Accounts payable

    89.5



    (75.0)



    45.9



    (74.4)

    Accrued interest

    9.2



    9.9



    (0.3)



    (0.6)

    Other assets and liabilities

    (2.9)



    (78.4)



    6.4



    (34.3)

    Other

    1.4



    (0.2)



    5.5



    1.3

    Net cash provided by operating activities

    281.1



    168.2



    422.7



    387.7

    Cash flows from investing activities:















    Capital expenditures

    (45.8)



    (30.1)



    (80.5)



    (58.1)

    Other

    0.9



    0.7



    1.4



    1.4

    Net cash used in investing activities

    (44.9)



    (29.4)



    (79.1)



    (56.7)

    Cash flows from financing activities:















    Debt borrowings

    (28.9)



    —



    12.3



    —

    Debt repayments

    (172.7)



    (190.8)



    (383.0)



    (460.3)

    Payments of debt refinancing fees and premiums

    —



    (2.3)



    —



    (2.3)

    Proceeds received from exercise of stock options

    5.3



    2.1



    50.8



    4.7

    Shares repurchased to satisfy employee tax

         obligations for vested stock-based awards

    (0.8)



    (5.2)



    (7.4)



    (13.3)

    Net cash used in financing activities

    (197.1)



    (196.2)



    (327.3)



    (471.2)

    Effect of currency rate changes on cash and cash equivalents

    (1.6)



    (0.7)



    (7.3)



    4.1

    Net change in cash, cash equivalents and restricted cash

    37.5



    (58.1)



    9.0



    (136.1)

    Cash, cash equivalents and restricted cash, beginning of period

    259.2



    318.9



    287.7



    396.9

    Cash, cash equivalents and restricted cash, end of period

    $    296.7



    $    260.8



    $    296.7



    $    260.8

     

    Avantor, Inc. and subsidiaries 

    Reconciliations of non-GAAP measures 



    Adjusted EBITDA and Adjusted EBITDA Margin 



    (dollars in millions)

    Three months ended June 30,



    Six months ended June 30,

    2024



    2023



    2024



    2023

    $



    %



    $



    %



    $



    %



    $



    %

    Net income (loss)

    $ 92.9



    5.5 %



    $  (7.3)



    (0.4) %



    $  153.3



    4.5 %



    $  114.2



    3.2 %

    Amortization

    74.9



    4.4 %



    78.9



    4.5 %



    150.2



    4.4 %



    157.3



    4.5 %

    Loss on extinguishment of debt

    1.9



    — %



    1.6



    0.1 %



    4.4



    0.1 %



    3.9



    0.1 %

    Integration-related expenses1

    —



    — %



    (0.6)



    — %



    —



    — %



    8.1



    0.2 %

    Restructuring and severance charges2

    9.7



    0.6 %



    7.2



    0.4 %



    32.9



    1.0 %



    11.9



    0.3 %

    Transformation expenses3

    16.2



    1.0 %



    —



    — %



    29.5



    0.9 %



    —



    — %

    Other4

    (0.3)



    — %



    (0.7)



    — %



    (0.8)



    — %



    (0.8)



    — %

    Impairment charges5

    —



    — %



    160.8



    9.2 %



    —



    — %



    160.8



    4.6 %

    Income tax benefit applicable to

         pretax adjustments

    (27.3)



    (1.6) %



    (53.5)



    (3.1) %



    (50.9)



    (1.5) %



    (73.6)



    (2.1) %

    Adjusted net income

    168.0



    9.9 %



    186.4



    10.7 %



    318.6



    9.4 %



    381.8



    10.8 %

    Interest expense, net

    60.9



    3.6 %



    73.4



    4.2 %



    125.2



    3.7 %



    147.1



    4.2 %

    Depreciation

    27.7



    1.5 %



    23.7



    1.4 %



    52.0



    1.6 %



    46.4



    1.4 %

    Income tax provision applicable

         to Adjusted Net income

    49.0



    2.9 %



    59.5



    3.4 %



    92.8



    2.7 %



    113.9



    3.2 %

    Adjusted EBITDA

    $  305.6



    17.9 %



    $  343.0



    19.7 %



    $  588.6



    17.4 %



    $  689.2



    19.6 %

    ━━━━━━━━━

    1.

    Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.

    2.

    Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. The expenses recognized in 2024 represent costs incurred to achieve the Company's publicly-announced cost transformation initiative.

    3.

    Represents incremental expenses directly associated with the Company's publicly-announced cost transformation initiative, primarily related to the cost of external advisors.

    4.

    Represents net foreign currency (gain) loss from financing activities, other stock-based compensation expense (benefit) and charges and legal costs in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.

    5.

    Related to impairment of the Ritter asset group.

     

    Avantor, Inc. and subsidiaries 

    Reconciliations of non-GAAP measures (continued) 



    Adjusted Operating Income and Adjusted Operating Income Margin 



    (dollars in millions)

    Three months ended June 30,



    Six months ended June 30,

    2024



    2023



    2024



    2023

    $



    %



    $



    %



    $



    %



    $



    %

    Net income (loss)

    $ 92.9



    5.5 %



    $  (7.3)



    (0.4) %



    $  153.3



    4.5 %



    $  114.2



    3.2 %

    Interest expense, net

    60.9



    3.6 %



    73.4



    4.2 %



    125.2



    3.7 %



    147.1



    4.2 %

    Income tax expense

    21.7



    1.3 %



    6.0



    0.3 %



    41.9



    1.2 %



    40.3



    1.1 %

    Loss on extinguishment of debt

    1.9



    — %



    1.6



    0.1 %



    4.4



    0.1 %



    3.9



    0.1 %

    Other income, net

    (1.6)



    (0.1) %



    (2.0)



    (0.1) %



    (2.7)



    — %



    (2.6)



    — %

    Operating income

    175.8



    10.3 %



    71.7



    4.1 %



    322.1



    9.5 %



    302.9



    8.6 %

    Amortization

    74.9



    4.4 %



    78.9



    4.5 %



    150.2



    4.4 %



    157.3



    4.5 %

    Integration-related expenses1

    —



    — %



    (0.6)



    — %



    —



    — %



    8.1



    0.2 %

    Restructuring and severance charges2

    9.7



    0.6 %



    7.2



    0.4 %



    32.9



    1.0 %



    11.9



    0.3 %

    Transformation expenses3

    16.2



    1.0 %



    —



    — %



    29.5



    0.9 %



    —



    — %

    Other4

    0.6



    — %



    0.9



    0.1 %



    0.9



    — %



    1.0



    — %

    Impairment charges5

    —



    — %



    160.8



    9.2 %



    —



    — %



    160.8



    4.6 %

    Adjusted Operating Income

    $  277.2



    16.3 %



    $  318.9



    18.3 %



    $  535.6



    15.8 %



    $  642.0



    18.2 %

    ━━━━━━━━━

    1.

    Represents direct costs incurred with third parties and the accrual of a long-term retention incentive to integrate acquired companies. These expenses represent incremental costs and are unrelated to normal operations of our business. Integration expenses are incurred over a pre-defined integration period specific to each acquisition.

    2.

    Reflects the incremental expenses incurred in the period related to restructuring initiatives to increase profitability and productivity. Costs included in this caption are specific to employee severance, site-related exit costs, and contract termination costs. The expenses recognized in 2024 represent costs incurred to achieve the Company's publicly-announced cost transformation initiative.

    3.

    Represents incremental expenses directly associated with the Company's publicly-announced cost transformation initiative, primarily related to the cost of external advisors.

    4.

    Represents other stock-based compensation expense (benefit) and charges and legal costs in connection with certain litigation and other contingencies that are unrelated to our core operations and not reflective of on-going business and operating results.

    5.

    Related to impairment of the Ritter asset group.

     

    Avantor, Inc. and subsidiaries 

    Reconciliations of non-GAAP measures (continued) 



    Earnings per share 



    (shares in millions)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2024



    2023



    2024



    2023

    Diluted earnings (loss) per share (GAAP)

    $      0.14



    $     (0.01)



    $      0.22



    $      0.17

    Dilutive impact of convertible instruments

    —



    —



    —



    —

    Fully diluted earnings (loss) per share (non-GAAP)

    0.14



    (0.01)



    0.22



    0.17

    Amortization

    0.11



    0.12



    0.22



    0.23

    Loss on extinguishment of debt

    —



    —



    0.01



    0.01

    Integration-related expenses

    —



    —



    —



    0.01

    Restructuring and severance charges

    0.02



    0.01



    0.05



    0.02

    Transformation expenses

    0.02



    —



    0.04



    —

    Other

    —



    —



    —



    —

    Impairment charges

    —



    0.24



    —



    0.24

    Income tax benefit applicable to pretax adjustments

    (0.04)



    (0.08)



    (0.07)



    (0.12)

    Adjusted EPS (non-GAAP)

    $      0.25



    $      0.28



    $      0.47



    $      0.56

















    Weighted average shares outstanding:















    Diluted (GAAP)

    682.6



    675.3



    681.9



    677.9

    Incremental shares excluded for GAAP

    —



    2.4



    —



    —

    Share count for Adjusted EPS (non-GAAP)

    682.6



    677.7



    681.9



    677.9

     

    Free cash flow 



    (in millions)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2024



    2023



    2024



    2023

    Net cash provided by operating activities

    $    281.1



    $    168.2



    $    422.7



    $    387.7

    Capital expenditures

    (45.8)



    (30.1)



    (80.5)



    (58.1)

    Free cash flow (non-GAAP)

    $    235.3



    $    138.1



    $    342.2



    $    329.6

     

    Adjusted net leverage 



    (dollars in millions)

    June 30, 2024

    Total debt, gross

    $      5,148.3

    Less cash and cash equivalents

    (272.6)



    $      4,875.7





    Trailing twelve months Adjusted EBITDA

    $      1,208.5

    Trailing twelve months ongoing stock-based compensation expense

    42.3



    $      1,250.8





    Adjusted net leverage (non-GAAP)

                  3.9 x

     

    Avantor, Inc. and subsidiaries 

    Reconciliations of non-GAAP measures (continued) 



    Net sales by segment 



    (in millions)

    June 30,



    Reconciliation of net sales growth

    (decline) to organic net sales growth

    (decline)



    Net sales

    growth

    (decline)



    Foreign

    currency

    impact



    Organic

    net sales

    growth

    (decline)



    2024



    2023



    Three months ended:





















    Laboratory Solutions

    $   1,155.7



    $   1,193.8



    $      (38.1)



    $        (5.4)



    $      (32.7)



    Bioscience Production

    547.1



    550.1



    (3.0)



    (1.3)



    (1.7)



    Total

    $   1,702.8



    $   1,743.9



    $      (41.1)



    $        (6.7)



    $      (34.4)



    Six months ended:





















    Laboratory Solutions

    $   2,312.8



    $   2,396.8



    $      (84.0)



    $         3.6



    $      (87.6)



    Bioscience Production

    1,069.8



    1,127.4



    (57.6)



    1.7



    (59.3)



    Total

    $   3,382.6



    $   3,524.2



    $    (141.6)



    $         5.3



    $    (146.9)



     

    Adjusted Operating Income by segment 



    (in millions)

    Three months ended

    June 30,



    Six months ended

    June 30,

    2024



    2023



    2024



    2023

    Laboratory Solutions

    $      150.9



    $      179.7



    $      299.1



    $      351.9

    Bioscience Production

    144.0



    154.2



    270.9



    321.7

    Corporate

    (17.7)



    (15.0)



    (34.4)



    (31.6)

    Total

    $      277.2



    $      318.9



    $      535.6



    $      642.0

     

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-reports-second-quarter-2024-results-302207246.html

    SOURCE Avantor and Financial News

    Get the next $AVTR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AVTR

    DatePrice TargetRatingAnalyst
    4/29/2025$14.00Buy → Neutral
    Goldman
    4/28/2025$15.50Buy → Hold
    TD Cowen
    4/28/2025$14.00Buy → Hold
    Stifel
    4/28/2025Overweight → Equal-Weight
    Morgan Stanley
    1/17/2025$29.00 → $25.00Buy → Neutral
    UBS
    8/28/2024$30.00Overweight
    Wells Fargo
    7/10/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    1/4/2024$19.50 → $26.00In-line → Outperform
    Evercore ISI
    More analyst ratings

    $AVTR
    Financials

    Live finance-specific insights

    See more
    • Avantor® Announces CEO Transition

      Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

      4/25/25 6:07:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Reports First Quarter 2025 Results

      Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

      4/25/25 6:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Report First Quarter 2025 Earnings on Friday, April 25, 2025

      RADNOR, Pa., March 28, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its first quarter 2025 financial results before the market opens on Friday, April 25, and will hold a conference call to discuss the results on the same day at 8:00 a.m. Eastern Daylight Time. To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorsciences.com. A repl

      3/28/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Summe Gregory L bought $300,000 worth of shares (25,000 units at $12.00) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/9/25 4:51:58 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Massaro Joseph R bought $99,630 worth of shares (8,100 units at $12.30), increasing direct ownership by 30% to 35,038 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      4/29/25 5:58:52 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Summe Gregory L bought $312,500 worth of shares (25,000 units at $12.50) (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      4/29/25 5:58:40 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Leadership Updates

    Live Leadership Updates

    See more

    $AVTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $AVTR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $AVTR
    SEC Filings

    See more
    • Avantor® Appoints Dame Louise Makin, DBE, Ph.D., to its Board of Directors

      RADNOR, Pa., Nov. 6, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that the Avantor Board of Directors has appointed Dame Louise Makin, DBE, Ph.D., as a director with an initial term expiring at Avantor's 2025 Annual Meeting of Stockholders. The appointment of Dame Louise as an independent director fills a vacant board seat. Dame Louise brings a wealth of leadership and industry experience to the Avantor Board. She served as Chief Executive Officer of BTG plc, an international specialist healthcare company, for 15 years and led their transform

      11/6/24 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Wheels Up Announces Gregory Summe to Join Board of Directors

      Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

      8/8/24 8:05:00 AM ET
      $AVTR
      $GRAL
      $NXPI
      $STT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Medical Specialities
      Health Care
    • Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600

      NEW YORK, July 23, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: Avantor Inc. (NYSE:AVTR) will replace QuidelOrtho Corp. (NASD:QDEL) in the S&P MidCap 400, and QuidelOrtho will replace Hibbett Inc. (NASD:HIBB) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 26. JD Sports Fashion Plc (XLON: JD) is acquiring Hibbett in a deal expected to close soon pending final closing conditions.Schneider National Inc. (NYSE:SNDR) will replace U.S. Silica Holdings Inc. (NYSE:SLCA) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 31. Apollo Global Management Inc. (NYS

      7/23/24 7:17:00 PM ET
      $APO
      $AVTR
      $HIBB
      $QDEL
      Investment Managers
      Finance
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • President Laboratory Solutions Walker Corey was granted 162,866 shares, increasing direct ownership by 229% to 234,001 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:49 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Carethers John was granted 17,100 shares, increasing direct ownership by 59% to 45,858 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:39 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP & Chief Accounting Officer Eck Steven W was granted 20,358 shares, increasing direct ownership by 51% to 59,929 units (SEC Form 4)

      4 - Avantor, Inc. (0001722482) (Issuer)

      5/12/25 5:35:27 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® to Participate in Bank of America Securities 2025 Health Care Conference

      RADNOR, Pa., May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m. Pacific Time.  To hear a live audio webcast of the session, visit Events & Presentations in the Investor section of Avantor's website, ir.avantorscience

      5/2/25 8:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Announces CEO Transition

      Board initiates search process to identify next CEO RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc., a leading global provider of mission-critical products and services for the life sciences and advanced technology industries, today announced that Michael Stubblefield intends to step down from his role as Director, President and Chief Executive Officer upon the appointment of a successor. The Board and Mr. Stubblefield agreed that now is the right time to initiate a leadership transition. The Board has initiated a search process to identify the Company's next CEO led

      4/25/25 6:07:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor® Reports First Quarter 2025 Results

      Net sales of $1.58 billion, decrease of 6%; organic decline of 2%Net income of $64.5 million; Adjusted EBITDA of $269.5 millionDiluted GAAP EPS of $0.09; adjusted EPS of $0.23Operating cash flow of $109.3 million; free cash flow of $82.1 millionAnnounces significant actions across the business to accelerate growth and enhance cost structure; increasing cost transformation target to $400 million in gross run-rate savings exiting 2027RADNOR, Pa., April 25, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE:AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first fiscal q

      4/25/25 6:05:00 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      5/12/25 5:16:45 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - Avantor, Inc. (0001722482) (Filer)

      4/28/25 8:29:56 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 10-Q filed by Avantor Inc.

      10-Q - Avantor, Inc. (0001722482) (Filer)

      4/25/25 9:00:12 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      11/14/24 1:28:33 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      8/9/24 3:22:24 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Avantor Inc.

      SC 13G/A - Avantor, Inc. (0001722482) (Subject)

      8/7/24 4:09:12 PM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $AVTR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Avantor downgraded by Goldman with a new price target

      Goldman downgraded Avantor from Buy to Neutral and set a new price target of $14.00

      4/29/25 8:05:35 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by TD Cowen with a new price target

      TD Cowen downgraded Avantor from Buy to Hold and set a new price target of $15.50

      4/28/25 8:32:10 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Avantor downgraded by Stifel with a new price target

      Stifel downgraded Avantor from Buy to Hold and set a new price target of $14.00

      4/28/25 8:31:49 AM ET
      $AVTR
      Biotechnology: Laboratory Analytical Instruments
      Industrials